Structure–activity relationship studies and <em>Plasmodium</em> life cycle profiling identifies pan-active N-aryl-3-trifluoromethyl... (Publications)
Structure-activity relationship studies involving N-aryl-3-trifluoromethyl pyrido[1,2-a] benzimidazoles (PBI) identified several compounds possessing potent in vitro activities against the asexual blo
Single-dose tafenoquine to prevent relapse of <em>Plasmodium vivax</em> malaria (Publications)
BACKGROUND: Treatment of Plasmodium vivax malaria requires the clearing of asexual parasites, but relapse can be prevented only if dormant hypnozoites are cleared from the liver (a treatment termed "radical
Early antischistosomal leads identified from<em> in vitro</em> and<em> in vivo</em> screening of the Medicines for Malaria Venture pathogen box (Publications)
Facing an almost dry drug development pipeline, screening the Pathogen Box from the Medicines for Malaria Venture (MMV), provides a unique opportunity to possibly expand the pool of potent molecules against
Adherence to intermittent preventive treatment for malaria in Papua New Guinean infants: a pharmacological study alongside the randomized controlled... (Publications)
(IPTi) trial that took place in Papua New Guinea showed an overall reduction of 29% of the risk of malaria when delivering single-dose sulfadoxine-pyrimethamine (SP) associated to 3 days of amodiaquine (AQ) [...] to discuss the efficacy of the intervention and on feasibility of self-administered preventive malaria treatment. METHODS AND FINDINGS: During the three-arm randomized double-blinded IPTi trial, each [...] studied when discussing the efficacy of the interventions in trials...
Impact of climate variability on the transmission risk of malaria in northern Côte d'Ivoire (Publications)
climate patterns might affect the transmission of malaria. The purpose of this study was to analyze climate and environmental parameters associated with malaria transmission in Korhogo, a city in northern Cote [...] (95% CI: 0.1 to 6.7%) in clinical malaria episodes. A 0.1 unit increase in monthly NDVI was associated with a 7.3% (95% CI: 0.8 to 14.1%) increase in the monthly malaria count. There was a similar increase [...] 2.3% to 11.2%)). The study results can be used to establish a malaria...
Safety, immunogenicity, and protective efficacy against controlled human malaria infection of<em> Plasmodium falciparum</em> sporozoites vaccine in... (Publications)
We are using controlled human malaria infection (CHMI) by direct venous inoculation (DVI) of cryopreserved, infectious Plasmodium falciparum (Pf) sporozoites (SPZ) (PfSPZ Challenge) to try to reduce time [...] time and costs of developing PfSPZ Vaccine to prevent malaria in Africa. Immunization with five doses at 0, 4, 8, 12, and 20 weeks of 2.7 x 10(5) PfSPZ of PfSPZ Vaccine gave 65% vaccine efficacy (VE) at [...] and controls. Antibody responses to Pf circumsporozoite protein were...
The candidate blood-stage malaria vaccine P27A induces a robust humoral response in a fast track to the field phase I trial in exposed and non exposed... (Publications)
The present project aimed at evaluating the safety and immunogenicity of P27A peptide vaccine in malaria non-exposed European and exposed African adults. Methods: This study was designed as a staggered [...] GLA-SE (2.5 or 5mug), or control rabies vaccine (Verorab(R)) were administered intramuscularly to 16 malaria non-exposed and 40 exposed subjects on days 0, 28 and 56. Local and systemic adverse events (AEs) [...] an ADCI dependent mechanism. Incidence of AEs and antibody responses were...
UCT943, a next generation <em>Plasmodium falciparum</em> PI4K inhibitor preclinical candidate for the treatment of malaria (Publications)
drug candidate inhibiting Plasmodium phosphatidylinositol 4-kinase (PI4K), a novel drug target for malaria, to enter clinical development. In an effort to identify the next generation of PI4K inhibitors, [...] single-exposure radical cure and prophylaxis (SERCaP) to treat, prevent and block the transmission of malaria.
